CC
SRRA

Caxton Corporation’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Caxton Corporation’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-262,969
Closed -$5.72M – 51
2021
Q4 		$5.72M Sell
262,969
-179,785
-41% -$3.96M 4.67% 7
2021
Q3 		$9.71M Sell
442,754
-1,205
-0.3% -$24.1K 7.86% 4
2021
Q2 		$8.64M Hold
443,959
– – 5.92% 7
2021
Q1 		$7.65M Sell
443,959
-200,000
-31% -$3.17M 4.97% 7
2020
Q4 		$10.3M Hold
643,959
– – 6.43% 6
2020
Q3 		$6.87M Hold
643,959
– – 6.48% 5
2020
Q2 		$7.79M Hold
643,959
– – 8.22% 4
2020
Q1 		$6.32M Buy
+643,959
New +$8.44M 6.91% 5
2018
Q4 		– Sell
-2,797
Closed -$190K – 32
2018
Q3 		$190K Buy
2,797
+1,954
+232% +$177K 0.18% 29
2018
Q2 		$100K Sell
843
-97
-10% -$9.73K 0.04% 23
2018
Q1 		$78K Buy
+940
New +$107K 0.08% 23
2016
Q1 		– Sell
-1,143
Closed -$688K – 22
2015
Q4 		$688K Hold
1,143
– – 2.89% 5
2015
Q3 		$938K Buy
+1,143
New +$1.29M 1.27% 3

Other funds holding SRRA

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Caxton Corporation's SRRA Position: Q1 2022 in Review

Caxton Corporation sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q1 2022, closing a stake of 262,969 shares — an estimated $5.72M sold.

Caxton Corporation first reported a position in SRRA in Q3 2015 and held it in 13 quarters. The position peaked at $10.3M in Q4 2020. 75 funds tracked by Wall St. Rank hold SRRA as of Q1 2022.

  • Caxton Corporation reported no remaining Sierra Oncology, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Caxton Corporation sold 262,969 Sierra Oncology, Inc. Common Stock shares in Q1 2022, an estimated $5.72M.
  • Caxton Corporation first reported a position in Sierra Oncology, Inc. Common Stock in Q3 2015 and held it in 13 quarters.
  • Caxton Corporation's Sierra Oncology, Inc. Common Stock position peaked at $10.3M in Q4 2020.
  • 75 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q1 2022.

Based on Caxton Corporation's 13F filing for Q1 2022, filed 16 May 2022.